The combination of FLT3 inhibitors (gilteritinib or sorafenib) with venetoclax could synergistically reduce cell proliferation and enhance apoptosis/cell death in FLT3/ITD cell lines and primary AML samples. Here, FLT3 is linked to acute myeloid leukemia.